Inhibition of succinimide formation in aqueous Zn-rHirudin suspensions
- PMID: 10554108
- DOI: 10.1023/a:1018925209080
Inhibition of succinimide formation in aqueous Zn-rHirudin suspensions
Abstract
Purpose: The formation of succinimide intermediates at Asp-Gly sites and their hydrolysis products, e.g., isoAsp isomers, represents a common source of microheterogeneity in therapeutic proteins. Here we report on the stabilization effect of a zinc chloride induced precipitation of recombinant hirudin HV1 (rHir), an anticoagulant protein.
Methods: rHir was precipitated by zinc chloride at neutral pH to form a Zn-rHir suspension. An Arrhenius-type study (at 50, 40, 30, and 25 degrees C) and a 4 degrees C stability study were performed. Monitoring of rHir, rHir succinimides at Asp33-Gly34 (Q5) and Asp53-Gly54 (Q4), and further side products was by capillary electrophoresis (CE).
Results: The activation energies of rHir degradation in both aqueous rHir solution and Zn-rHir suspension were similar, i.e. 104.5 and 110.3 kJ/mol, respectively. Zn-rHir suspension demonstrated improved shelf-life stability (t90%, 95% confidence limit) versus rHir solution, i.e., 23 versus 3 days at 25 degrees C and 292 versus 147 days at 4 degrees C, respectively. In rHir solution, Q4 (Asp53-Gly54 succinimide) levels were slightly above Q5 (Asp33-Gly34 succinimide) levels. In Zn-rHir suspension, however, Q4 succinimide levels dropped markedly whereas Q5 levels were not affected. Correspondingly, in Zn-rHir isoAsp53-rHir levels were reduced but not isoAsp33-rHir levels.
Conclusions: In Zn-rHir suspensions, interactions of zinc and rHir show site-specific inhibition of succinimide formation only at Asp53-Gly54 (Q4), located in the highly flexible C-terminal tail of rHir. In contrast, succinimide formation at Asp33-Gly34 (Q5), located in a less flexible loop domain is not affected, reflecting steric hindrance.
Similar articles
-
Chemical degradation kinetics of recombinant hirudin (HV1) in aqueous solution: effect of pH.Pharm Res. 1998 Sep;15(9):1456-62. doi: 10.1023/a:1011918108849. Pharm Res. 1998. PMID: 9755900
-
Formulation of sustained release aqueous Zn-hirudin suspensions.Eur J Pharm Sci. 2000 Jul;11(1):33-41. doi: 10.1016/s0928-0987(00)00072-5. Eur J Pharm Sci. 2000. PMID: 10913751
-
Sustained release of injectable zinc-recombinant hirudin suspensions: development and validation of in vitro release model.Eur J Pharm Biopharm. 1998 May;45(3):259-64. doi: 10.1016/s0939-6411(98)00008-3. Eur J Pharm Biopharm. 1998. PMID: 9653630
-
Characterization of succinimide-type dehydration products of recombinant hirudin variant 1 by electrospray tandem mass spectrometry.Rapid Commun Mass Spectrom. 1993 Dec;7(12):1082-5. doi: 10.1002/rcm.1290071205. Rapid Commun Mass Spectrom. 1993. PMID: 8280917
-
Sequence-specific deamidation: isolation and biochemical characterization of succinimide intermediates of recombinant hirudin.Biochemistry. 1993 Jan 19;32(2):725-34. doi: 10.1021/bi00053a042. Biochemistry. 1993. PMID: 8422378
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical